Is evantumumab an immunological drug or a targeted drug?

Evantumumab (amivantamab) is a targeted therapy drug that also has immunotherapy characteristics. It is a bispecific antibody that specifically targets two oncogenic targets, epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (MET). The drug's trade name after its launch is Rybrevant, and it is mainly used to treat patients with metastatic non-small cell lung cancer (NSCLC) carrying EGFR exon 20 insertion mutations.

As a new bispecific antibody drug, evantumumab’s mechanism has dual effects of targeting and immunity: on the one hand, it binds to EGFR and MET receptors on the surface of tumor cells, blocking signaling pathways and inhibiting the proliferation and survival of cancer cells; on the other hand, it can also activate natural killer cells and macrophages in the human immune system through antibody-dependent cell-mediated cytotoxicity (ADCC) and phagocytosis (ADCP), thereby enhancing the ability to clear tumors. These mechanisms of action of evantumumab make it classified as a "targeting + immune" bifunctional drug, but from the perspective of drug classification, it is still mainly classified as a targeted therapy drug.

Clinically, evantumumab is suitable for patients with EGFR Exon 20 insertion mutation non-small cell lung cancer whose disease has progressed after previously receiving platinum-containing chemotherapy. It solves the problem of poor efficacy of traditional EGFR-TKI drugs for this mutation type. The drug is given as an intravenous infusion. Side effects include infusion reactions, rash, low white blood cell count, etc., but are generally well tolerated. The advent of evantumumab provides new treatment hope for NSCLC patients, especially in the treatment dilemma of EGFR exon 20 insertion mutations, which has shown significant efficacy.

In general, evantumumab is an innovative therapeutic drug with precise targeting and immunomodulatory functions, and represents the future trend of integrated development of precision tumor treatment and immunotherapy.

Reference materials:https://www.rybrevant.com/